Vitiligo is caused by autoreactive CD8+ T cells that react against skin melanocytes, where IL-15 has been shown to activate these T cells. Innovent Biologics (Suzhou) Co. Ltd. recently presented data on their monoclonal antibody (mAb) – IBI-3013 – that targets IL-15. IBI-3013 was evaluated in vitro in immune cell expansion and CD8 T-cell activation assays, as well as in vivo in a skin inflammation model and in a graft-vs.-host disease (GVHD) model.

Is there a link between cellular senescence and multiple sclerosis (MS) progression? Several presentations at this year’s European Committee for Treatment and Research in Multiple Sclerosis 2025 (ECTRIMS 2025) conference, which ends today in Barcelona, addressed this question.

Aera Therapeutics Inc. has nominated AERA-109, a targeted in vivo CAR T therapy designed to treat multiple B cell-mediated autoimmune diseases, as the company’s first development candidate. AERA-109 leverages Aera’s proprietary targeted lipid nanoparticle (tLNP) delivery platform and CAR T technology.

Clarivate plc has unveiled the 2025 Citation Laureates. Widely considered a predictor of the Nobel Prizes, this recognition has highlighted the discovery of biomolecular condensates in chemistry and the innate immunity signaling pathway in physiology or medicine, as well as the identification of leukemia stem cells and ghrelin, the so-called hunger hormone.

GC Biopharma Corp. has filed an IND application with the South Korean Ministry of Food and Drug Safety (MFDS) for a phase I trial of GC-4006A, an mRNA vaccine candidate for COVID-19.

The FDA has cleared HDT Bio Corp.’s IND application for HDT-321, a first-in-class prophylactic designed to protect against Crimean-Congo hemorrhagic fever (CCHF).

Dualitas Therapeutics Inc. exited stealth mode with a $65 million series A investment that was co-led by Versant Ventures and Qiming Venture Partners USA.